循环与尿液microRNA谱预测重症急性肾损伤的肾功能恢复
这项前瞻性观察研究于2020年6月至2021年1月纳入AKI 3期患者,分肾功能恢复组与未恢复组,用nCounter miRNA表达检测做转录组分析,再用qRT-PCR验证候选miRNA。发现阶段在尿液和血清中分别识别出18个和11个组间差异有统计学意义的miRNA。验证阶段共110例,尿miR-556-3p在恢复组显著高于未恢复组,单独预测恢复AUC 0.64(95%CI 0.52-0.75,p=0.03),临床模型联合尿miR-556-3p预测AUC 0.83(95%CI 0.75-0.92,p<0.01)。提示尿miR-556-3p有潜力改善重症AKI肾功能恢复的预测。
要点
- 验证阶段共110例AKI 3期患者,尿miR-556-3p在肾功能恢复组显著高于未恢复组。
- 尿miR-556-3p单独预测肾功能恢复AUC 0.64(95%CI 0.52-0.75,p=0.03)。
- 临床模型联合尿miR-556-3p预测肾功能恢复AUC 0.83(95%CI 0.75-0.92,p<0.01)。
- 发现阶段尿液和血清中分别有18个和11个miRNA在恢复组与未恢复组间差异有统计学意义。
- 尿液候选miRNA包括miR-556-3p、miR-1915-3p、miR-4284、miR-32-5p、miR-96-5p、miR-556-5p,血清候选包括miR-499b-5p、miR-30a-3p、miR-92b-3p、miR-770-5p。
适用人群与场景
- AKI 3期患者,来自肾功能恢复组与肾功能未恢复组,尿液和血清样本用于miRNA检测。
研究设计与关键结果
- 研究类型为前瞻性观察研究,时间2020年6月至2021年1月,验证阶段纳入110例AKI 3期患者。
- 发现阶段用nCounter miRNA表达检测,尿液和血清中分别识别出18个和11个组间差异有统计学意义的miRNA。
- 验证阶段用qRT-PCR,尿miR-556-3p在肾功能恢复组显著高于未恢复组。
- 尿miR-556-3p单独预测肾功能恢复AUC 0.64(95%CI 0.52-0.75,p=0.03)。
- 临床模型联合尿miR-556-3p预测肾功能恢复AUC 0.83(95%CI 0.75-0.92,p<0.01)。
证据类型、等级与局限
- 证据类型:前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为尿miR-556-3p有潜力改善重症AKI肾功能恢复的预测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is little known about the contribution of microRNAs (miRNAs) in the recovery from acute kidney injury (AKI). This study aimed to discover and validate miRNA profiles for predicting renal recovery from severe AKI.
PATIENTS AND METHODS: A prospective observational study was conducted between June 2020 and January 2021. Urine and serum samples of participants with AKI stage 3 were collected from two groups: renal recovery and renal non-recovery. Transcriptomic analysis was performed using nCounter miRNA Expression Assay. Expression levels of candidate miRNAs were validated using quantitative real-time polymerase chain reaction (qRT-PCR).
RESULTS: The discovery phase identified 18 and 11 differentially expressed miRNAs that were statistically significant between the two groups in urine and serum specimens, respectively. Top candidate miRNAs selected included miR-556-3p, miR-1915-3p, miR-4284, miR-32-5p, miR-96-5p, and miR-556-5p in urine, and miR-499b-5p, miR-30a-3p, miR-92b-3p and miR-770-5p in serum. This study enrolled 110 participants in the validation phase. The qRT-PCR analysis indicated that urine miR-556-3p was significantly higher in the renal recovery group than in the renal non-recovery group. Urine miR-556-3p alone predicted renal recovery with an area under the curve (AUC) of 0.64 (95%CI 0.52-0.75, p = 0.03). Combining the clinical model with urine miR-556-3p predicted renal recovery with an AUC of 0.83 (95%CI 0.75-0.92, p < 0.01).
CONCLUSION: This data provides evidence that microtranscriptome profiles of severe AKI patients with renal recovery differed from the non-recovery group. Urine miR-556-3p had the potential to improve the prediction of renal recovery from severe AKI.
参考来源
- Phulkerd T, Lertussavavivat T, Limothai U, et al. Circulating and urinary microRNAs profile for predicting renal recovery from severe acute kidney injury. J Intensive Care. 2022. PMID: 36180946. doi:10.1186/s40560-022-00637-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。